Document:

Amendment No. 2 to Development, Commercialization and Licensing Agreement

 Exhibit 10.13 
 AMENDMENT NO. 2 
 TO 
 DEVELOPMENT, COMMERCIALIZATION AND LICENSING AGREEMENT 
 This Amendment
No. 2 to Development, Commercialization and Licensing Agreement (the “Amendment”) is made and effective as of May         , 2008, by and between Laboratory Corporation of America Holdings
(“LabCorp”) and ARCA Discovery, Inc. (“ARCA”). 
 WHEREAS, LabCorp and ARCA entered into a Development, Commercialization
and Licensing Agreement dated February 1, 2007, which was amended pursuant to an Amendment No. 1 dated May 14, 2007 (as amended, the “License Agreement”), and 
 WHEREAS, the parties desire to further amend the terms of the License Agreement. 
 NOW, THEREFORE, in consideration of the promises and mutual covenants of the parties and other good valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, LabCorp and ARCA agree to the following amendments to the License Agreement: 
 1. Inclusion of LabCorp Wholly-Owned
Subsidiaries as Licensees. 
 a. Section 2.1 of the License Agreement shall be amended by deleting the parenthetical that currently
states “(and to those Affiliates [ * ]”, and replacing it with “[ * ]. 
 b. Section 2.8 of the
License Agreement is hereby deleted in its entirety. 
 c. Section 10.2(j) of the License Agreement is hereby deleted in its entirety.

 d. Exhibit A of the License Agreement is hereby deleted in its entirety. 
 e. For informational purposes, attached as Exhibit A to this Amendment is a list of wholly-owned subsidiaries of LabCorp as of the date of this
Amendment. 
 2. Permitted Sublicensees. 
 a. In Section 2.6 of the License Agreement, the [ * ] are hereby deleted and
replaced with [ * ]. 
 b. Exhibit B of the License Agreement is hereby deleted in its entirety and replaced with Exhibit
B of this Amendment. 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

 c. The following language shall be added to the end of Section 2.6: “ARCA expressly
acknowledges that LabCorp shall be permitted to enter into a sublicense with [ * ], subject to the terms of this Section 2.6, [ * ]. If LabCorp enters into a sublicense with [ * ] shall be deemed to be
LabCorp’s [ * ] sublicensee [ * ] under this Section 2.6.” 
 3. A new Section 3.10 shall be added, as follows:
“3.10 Additional Committees. The Parties agree that it is desirable to delegate certain responsibilities of the Diagnostics Committee to subcommittees with more narrowly defined responsibilities. The following subcommittees shall be set up
within 30 days of the date of Amendment No. 2 to this Agreement, each with the specific responsibilities as set forth below. The Diagnostics Committee shall retain the responsibility for approving each of the deliverables identified below. Each
Party, acting through its individual representatives on the subcommittees, shall have an obligation to use commercially reasonable efforts to complete these deliverables within the applicable timelines. The obligations set forth in this new
Section 3.10 shall supersede any inconsistent obligations in any other provision of this Agreement: 
 [ * ] 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

 
[ * ] 
 4. Removal of Prior Deadlines. In Sections 4.3 and 5.2 (relating to the Regulatory Plan and Commercial Plan), in the last sentence before clause (a) of each such Section, the words “will be completed within [ * ]
and” shall be deleted. In Section 5.3, the following sentence shall be deleted: “A proposed Marketing and Sales Plan will be distributed to the Diagnostics Committee within [ * ] and an approved Marketing and Sales Plan
shall be completed within [ * ] 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

 
[ * ] 
 5. No Other Amendments. Except as
otherwise amended by this Amendment, all other terms and conditions in the License Agreement will remain in full force and effect. This Amendment shall be governed by and construed according to the laws of the State of Delaware. 
 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective duly authorized officers or representatives as of the dates shown
below. 
  

									
	ARCA Discovery, Inc.	 		 	Laboratory Corporation of America Holdings
					
	By:	 	/s/ Christopher Ozeroff	 		 	By:	 	/s/ Bradford T. Smith

									
	Name:	 	Christopher Ozeroff	 		 	Name:	 	Bradford T. Smith
	Title:	 	EVP Bus. Dev. & GC	 		 	Title:	 	Executive Vice President
	Date:	 	June 10, 2008	 		 	Date:	 	June 6, 2008

  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

 EXHIBIT A 
 WHOLLY-OWNED SUBSIDIARIES OF LABCORP 
 [ * ] 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

 EXHIBIT B 
 PERMITTED SUBLICENSEES 
 [ * ] 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended.Unrestricted Research Grant with the University of Colorado, dated July 27, 2007

 Exhibit 10.14 
 

 
 1200 17th Street, Suite 620 
 Denver, Colorado 80202 

Phone: 303-893-1599, Fax: 303-825-0883 
 July 27, 2007 
 Michael R. Bristow, M.D., PhD. 
 Division of Cardiology 
 University of Colorado Health Sciences Center 
 Denver, CO 80262 
 Dear Michael, 
 ARCA Discovery, Inc. wishes to make unrestricted gifts to the University of Colorado Foundation in support of your laboratory and the research associated with heart
failure. We direct these contributions to be allocated as summarized below. 
  

						
	 •       Lab Personnel Costs -
	    	$	197,000	 	annually
	 •       General Laboratory Costs
	    	 	90,000	 	annually
		    	 	 	 	
	Total Commitment	    	$	287,000	 	
		    	 	 	 	

 ARCA expects to fund this commitment through monthly payments of $23,917. These payments are contingent upon
ARCA’s financial condition, therefore this arrangement can be terminated at ARCA’s discretion. The effective date of the arrangement is July 1, 2007. 
  

	
	Sincerely,
	
	/s/ Richard B. Brewer
	Richard B. Brewer
	President & CEO

  

			
	Acknowledged:	 	/s/ Michael Bristow
		 	Michael Bristow, M.D., PhD.

 ARCA Discovery, Inc 
 INTERNAL USE ONLY 
 (Annual Costs) 
  

					
	 Name
	  	 Estimated Percentage of Salary Supported
	  	Amount of
Contribution
	 [ * ]
	  	[ * ]	  	[ * ]

  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended.Unrestricted Research Grant with the University of Colorado

 Exhibit 10.15 
 

 
 8001 Arista Place, Suite 200 
 Broomfield, CO 80021 
 Phone: 720-940-2200, Fax: 720-208-9261 
 January 16, 2009 
 Michael R. Bristow, M.D.,
PhD. 
 Division of Cardiology 
 University of
Colorado Health Sciences Center 
 Denver, CO 80262 
 Dear Michael, 
 ARCA biopharma, Inc. wishes to make unrestricted gifts to the University of Colorado Foundation in support of your
laboratory and the research associated with heart failure during the 2008/2009 academic year. We hope that our contributions can support your laboratory costs as summarized below: 
  

						
	 •        Lab Personnel Costs -
	    	$	152,000	 	annually
	 •        General Laboratory Costs
	    	 	90,000	 	annually
		    	 	 	 	
	Total Commitment	    	$	242,000	 	
		    	 	 	 	

 ARCA expects to fund this commitment through monthly payments of $20,167. These payments are contingent upon
ARCA’s financial condition, therefore this arrangement can be terminated at ARCA’s discretion. The effective date of the arrangement is July 1, 2008. 
  

	
	Sincerely,
	
	/s/ Richard B. Brewer
	Richard B. Brewer
	President & CEO

  

			
	Acknowledged:	 	/s/ Michael Bristow
		 	Michael Bristow, M.D., PhD.

 ARCA biopharma, Inc 
 INTERNAL USE ONLY 
 (Annual Costs) 
  

					
	 Name
	  	 Estimated Percentage of Salary Supported
	  	Amount of
Contribution
	 [ * ]
	  	[ * ]	  	[ * ]

  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended.Materials Transfer Agreement, dated October 14, 2005

 Exhibit 10.16 
 UNIVERSITY OF COLORADO MATERIALS TRANSFER AGREEMENT 
 Parties 
 This is an Agreement, dated October 14, 2005 (the “Effective Date”), between the Regents of the
University of Colorado, a body corporate, contracting on behalf of the University of Colorado Health Sciences Center (“UCHSC”), and ARCA Discovery, Inc., a Delaware corporation with a principal place of business located at 1400
16th Street, Suite 220, Denver, CO 80202 (“Recipient”). 
 Materials 
 Biological materials to which this Agreement applies: one or more samples, to be specified by Recipient,
from the Human Cardiac Tissue Bank of the Department of Cardiology at the UCHSC (“Biological Materials”), and any related information or material supplied in connection therewith. 
 Whereas, UCHSC owns and is in possession of Biological Materials and has a right to provide said Biological Materials to Recipient as provided under this Agreement;

 Whereas, Recipient is conducting specific research activities described in the research plan set forth in Appendix A (“Research”); 

Now therefore, to protect UCHSC’s proprietary interests with respect to the Biological Materials, UCHSC agrees to provide Biological Materials to Recipient for
purposes of conducting the Research, subject to the following terms and conditions: 
  

	1.	

  

	 	(a)	Recipient shall reimburse UCHSC thirty-five thousand dollars ($35,000) of the annual costs of support incurred by UCHSC to meet the obligations of this Agreement. Such annual
payment shall be due in quarterly installments of eight thousand seven hundred and fifty dollars ($8,750) payable thirty (30) days from the first day of each quarter. The parties acknowledge that Recipient is current on such payments through
September 30, 2005. 

  

	 	(b)	Recipient shall reimburse UCHSC fifty percent (50%) of the costs for equipment upkeep and replacement, and fifty percent (50%) of the costs for tissue procurement, such
payments not to exceed ten thousand dollars ($10,000) for any given year without Recipient’s prior approval; provided that UCHSC may terminate this agreement if Recipient declines to approve such excess amounts within ninety (90) days
after written request from UCHSC. Such payments shall be due within thirty (30) days of invoice by the UCHSC Cardiology administrator. 

  

	 	 (c)
	 Payments more than sixty (60) days past due shall bear interest at the rate of one and one-half percent (1 1/2 %) per month compounded, or the maximum interest rate allowable by applicable law, whichever is less.

  

 1 

	 	(d)	Nothing in this Agreement requires UCHSC to provide Biological Materials to Recipient in amounts that would prohibit or substantially hinder UCHSC from carrying on its own research.

  

	2.	Recipient agrees that Biological Materials may be used solely in Recipient’s facilities, or such other party’s facilities as the Recipient and UCHSC shall agree to in
writing or as otherwise permitted under Section 3 below, and that Recipient will follow all applicable NIH guidelines. 

  

	3.      (a)	Recipient must maintain control of Biological Materials and may not transfer control to third parties, except as otherwise permitted under this Section 3, without the prior
written consent of UCHSC, and whose consent will not be unreasonably withheld. 

  

	 	(b)	Recipient may provide samples of the Biological Materials to any third party for chemical or biological analysis and testing, where such third party has entered into a collaborative
research and development agreement with Recipient or when the information from such analysis may be commercialized by Recipient or by third parties under an agreement with Recipient; provided that Recipient notifies UCHSC of any third party
that has been provided samples of the Biological Materials. 

  

	 	(c)	In the event that a third party is provided commercial rights to the data derived from the chemical and/or genetic analysis of the Biological Materials, Recipient will use
commercially reasonable efforts to negotiate a cost-free subscription for UCHSC for nonprofit research purposes to the commercial database of such third party containing data derived from the chemical and/or genetic analysis of the Biological
Materials. The subscription would preferably freely permit UCHSC’s use of the subscription database(s) for the purpose of grant or contract preparation and submittal to a non-profit or government agency for research funding and UCHSC research
use, and publication of UCHSC’s own research results (subject to UCHSC’s obligation to take reasonable steps prior to publication to protect ARCA intellectual property rights). In the event that Recipient cannot provide UCHSC with access
to the commercial database of such third party under the terms described above, Recipient will use commercially reasonable efforts to make data that Recipient receives from third party analysis available to UCHSC for purposes of grant or contract
preparation and submittal to a non-profit or government agency, for funding of UCHSC’s nonprofit research use. 

  

	 	(d)	Recipient’s use of Biological Materials pursuant to this Agreement shall comply with the non-competition and other provisions of the Strategic Alliance Agreement between ARCA
and Myogen, Inc., dated October 7, 2005. 

  

	4.	

  

	 	(a)	Nothing in this Agreement grants Recipient rights under any patents or in any know-how of UCHSC. 

  

	 	(b)	UCHSC places no restrictions other than those specified in this Agreement on Recipient’s use of Biological Materials. 

  

 2 

	 	(c)	UCHSC will not make claims to test data, results, lab notes, reports or other works created or prepared without use of UCHSC funds, facilities, or personnel acting in their capacity
as UCHSC employees, and Recipient shall own exclusively all intellectual property or other rights in any such test data, results, lab notes, reports or other works created or prepared using the Biological Materials. 

  

	5.	BIOLOGICAL MATERIALS ARE PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. RECIPIENT AGREES THAT UCHSC AND
ITS EMPLOYEES AND AGENTS HAVE NO LIABILITY IN CONNECTION WITH BIOLOGICAL MATERIALS PROVIDED UNDER THIS AGREEMENT OR THEIR USE BY RECIPIENT UNDER THIS AGREEMENT. 

 RECIPIENT AGREES TO INDEMNIFY UNIVERSITY FOR LIABILITY , LOSS, OR DAMANGE THEY MAY SUFFER AS A RESULT OF CLAIMS, DEMANDS, COSTS OR JUDGMENTS AGAINST
UNIVERSITY ARISING OUT OF THE ACTIVITIES TO BE CARRIED OUT PURSUANT TO THIS AGREEMENT. 
  

	6.	This Agreement will terminate on the earliest of the following dates: (i) five (5) years from the Effective Date; (ii) when Recipient determines that it has obtained
all required Biological Materials and states so in writing; (iii) when UCHSC’s supply of Biological Materials becomes exhausted; (iv) when all other business agreements, such as patent licenses, between Recipient and UCHSC or its
agents have terminated; (v) immediately after any continuous fifteen (15) month period in which Recipient fails to make the support payments specified in Article 1. In the event this Agreement terminates pursuant to clause (i) of this
Section 6, Recipient will have the option to renew this Agreement under substantially similar terms. 

  

	7.	UCHSC and Recipient will make reasonable efforts to monitor the supply and use of samples from the Heart Tissue Bank in order to assure that each entity maintains an adequate supply
of tissue in amounts that would not prohibit or substantially hinder UCHSC from carrying on its own research or commercial activities. 

  

	8.	This Agreement sets forth the entire agreement and understanding between the parties regarding the subject matter herein and cannot be changed or amended except by written agreement
executed by both parties. This Agreement may be assigned to a party that acquires substantially all of the assets of Recipient upon thirty (30) days prior written notice to UCHSC. A change in control of Recipient shall not be considered an
assignment of this Agreement. 

  

	9.	Any notice or communication permitted or required hereunder must be in writing. 

  

	10.	All waivers to this Agreement must be in writing. The failure of either party to insist upon strict performance of any provision of this Agreement, or to exercise any right provided
for herein, shall not be deemed to be a waiver for the future of such provision or right, and no waiver or any provision or right shall affect the right of the waiving party to enforce any other provision or right herein. 

 

 3 

	11.	This Agreement will be governed by and interpreted in accordance with the laws of the State of Colorado as those laws are applied to contracts entered into and to be performed
entirely in Colorado by Colorado residents. Venue for purposes of filing any legal action arising out of or in connection with this Agreement shall lie in Denver, Colorado which shall be deemed to be a convenient forum. 

  

	12.	If any provision of this Agreement is determined to be unenforceable for any reason, the remaining provisions hereof shall be unaffected and remain in full force and effect.

  

	13.	This Agreement may be executed in several counterparts, all of which shall constitute one agreement. This Agreement may be executed and delivered by facsimile.

 The authorized signatures below verify agreement between the parties. 
  

									
	For UCHSC	 		 	For Recipient
		 		 	ARCA Discovery, Inc.
			
	/s/ David N. Allen	 		 	/s/ Timothy D. Hoogheem
	David N. Allen	 		 	Timothy D. Hoogheem
	Director, Technology Transfer Office	 		 	Chief Business and Financial Officer
	University of Colorado	 		 	1400 16th Street
	4001 Discovery Drive, Suite 390	 		 	Suite 220
	Boulder Colorado, 80309	 		 	Denver, CO 80202
	Date:	 	October 14, 2005	 		 	Date:	 	October 14, 2005

  

 4 

 Exhibit A 
 Research Plan: ARCA Discovery, Inc. will use the Human Cardiac Tissue Bank for cardiovascular therapeutic research, particularly discovery and characterization of genetic polymorphisms that impact the natural history of cardiovascular
disease, and development of therapeutics and diagnostics to treat patients, where the diagnosis and/or indications will be guided by the presence or absence of these polymorphisms. 
  

 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}]]